XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 80 filers reported holding XENON PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $74,401 | -22.7% | 2,178 | -50.0% | 0.00% | +50.0% |
| Q2 2023 | $96,264 | +1588.8% | 4,356 | +335.6% | 0.00% | – |
| Q1 2023 | $5,700 | +94900.0% | 1,000 | 0.0% | 0.00% | – |
| Q4 2022 | $6 | -99.9% | 1,000 | 0.0% | 0.00% | – |
| Q3 2022 | $6,000 | 0.0% | 1,000 | 0.0% | 0.00% | – |
| Q2 2022 | $6,000 | -50.0% | 1,000 | -50.0% | 0.00% | – |
| Q1 2022 | $12,000 | -61.3% | 2,000 | +100.0% | 0.00% | -100.0% |
| Q4 2021 | $31,000 | +106.7% | 1,000 | 0.0% | 0.00% | – |
| Q3 2021 | $15,000 | -21.1% | 1,000 | 0.0% | 0.00% | – |
| Q2 2021 | $19,000 | +5.6% | 1,000 | 0.0% | 0.00% | – |
| Q1 2021 | $18,000 | +20.0% | 1,000 | 0.0% | 0.00% | -100.0% |
| Q4 2020 | $15,000 | +36.4% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $11,000 | -8.3% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $12,000 | +9.1% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $11,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 266,961 | $9,119,388 | 10.70% |
| COMMODORE CAPITAL LP | 1,845,000 | $63,025,200 | 7.37% |
| TLS Advisors LLC | 32,956 | $1,126 | 4.56% |
| Altium Capital Management LP | 228,000 | $7,788,480 | 4.06% |
| Paradigm Biocapital Advisors LP | 1,491,835 | $50,961,084 | 3.46% |
| GREAT POINT PARTNERS LLC | 500,001 | $17,080,034 | 3.11% |
| DAFNA Capital Management LLC | 280,538 | $9,583,178 | 2.98% |
| Nan Fung Group Holdings Ltd | 106,680 | $3,644,189 | 2.95% |
| Affinity Asset Advisors, LLC | 300,438 | $10,262,962 | 2.89% |
| Avoro Capital Advisors LLC | 4,900,000 | $167,384,000 | 2.61% |